AGI.do

Products

What will AGI do for Afatinib?

This classification denotes a quinazoline and antineoplastic agent and tyrosine kinase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 41UD74L59M. European Medicines Agency schedules Afatinib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32268. As of Q4 2014, AFATINIB remains the US FDA Preferred Term for this commodity. Afatinib bears US NLM identifiers UMLS ID C1879772 and NCI Concept Code C66940. SMILES: CN(C)C/C=C/C(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)O[C@H]4CCOC4.

How AGI delivers it

Four ways AGI delivers for Afatinib

  • Headless SaaS for Agents

    Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

    For Afatinib, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

  • Services-as-Software

    Get the professional outcome delivered as software, priced on results, not headcount.

    For Afatinib, get the professional outcome delivered as software, priced on results, not headcount.

Value flow

How Afatinib connects

measured by

  • Active Ingredient Assaymodel
  • Assay Puritymodel
  • Content Uniformitymodel
  • Dissolution Ratemodel
  • Tablet Hardnessmodel

Go deeper

Explore Afatinib

Read the deeper take on agi.asView as markdown